Nils Krüger

New Capabilities

As of August 2026: Published findings in The BMJ, August 2026

The FDA approved tirzepatide (Mounjaro) on August 28 to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes at high risk. The decision rests on SURPASS-CVOT, a 13,000-patient trial that found tirzepatide matched an older GLP-1 medicine, dulaglutide (Trulicity), on major heart events, with an estimated 8% lower rate.

Updated Aug 29